Compositions and methods for controlling drug loss and delivery in transdermal drug delivery systems

Abstract

A transdermal delivery system is provided for the topical application of one or more active agents contained in one or more polymeric and / or adhesive carrier layers, proximate to a non-drug containing polymeric and / or adhesive coating that is applied to either the transdermal system's backing or release liner. The transdermal delivery device is manufactured to optimize drug loading while providing desirable adhesion to skin or mucosa as well as providing modulation of the drug delivery and profile.

Description

TECHNICAL FIELD[0001]In accordance with 35 U.S.C. §119 (e), the benefit of provisional application 60 / 515,306, filed Oct. 28, 2003, is hereby claimed. The entire contents of this provisional application are incorporated herein by reference.[0002]This invention relates generally to transdermal drug delivery systems, and more particularly to pharmaceutically acceptable adhesive matrix compositions. The invention additionally relates to transdermal drug delivery systems where the drug permeation, delivery rates and profiles can be selectively modulated within the transdermal drug delivery system.[0003]The present invention relates to transdermal delivery systems, their method of making and method of use. In particular, the present invention is directed to a transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and / or adhesive carrier layers, proximate to a non-drug containing polymeric and / or adhesive coating that i...

AI Technical Summary

Benefits of technology

[0017]Another object is to provide a transdermal system, which is simple and inexpensive to manufacture, while preventing or minimizing drug loss and / or other volatile components in the composition. The present invention provides a transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and / or adhesive carrier layers, proximate to a non-drug containing polymeric and / or adhesive coating that is applied to either the transdermal system's backing or release liner, manufactured to optimize drug loading while providing desirable adhesion to skin or mucosa as well as providing modulation of the drug delivery and profile.

Problems solved by technology

However, when addressing all the design and performance factors and considerations to achieve the goal, this system alone cannot always provide the best method.

Depending on the active agent itself or the dosage necessary to be therapeutically effective, the amount of drug needed to be incorporated into a single, adhesive carrier or matrix composition (i.e., drug loading) can adversely affect or be adversely affected by, such carrier or matrix.

This is particularly problematic for drugs that are controlled substances (for which the Food and Drug Administration requires strict accounting for during the manufacturing process) and / or drugs that have relatively low boiling or melting points, such as low molecular weight drugs and drugs in their free base form.

Another problem often encountered with low molecular weight drugs, particularly those that are liquid at or near room temperature, is the plasticizing effect that such drugs have on the carrier polymers in the transdermal drug delivery system.

Namely, the composition becomes “leggy or gummy” resulting in sufficient loss of adhesive and / or cohesive properties and therefore unsuitable for sticking to the skin or mucosa of the user.

While using low drug concentrations may decrease the deleterious affects to the carrier's adhesive or cohesive properties, low concentration can result in difficulties in achieving an acceptable delivery rate and the drug may still be lost during processing.

Similarly, increasing polymer concentrations by increasing thickness or surface area of the carrier composition provides little flexibility in effectively controlling the release rate of a variety of drugs.

Formulating with low molecular weight drugs that are liquid at or near room temperatures is further particularly difficult in adhesive carrier layer compositions because such drugs more readily or easily permeate skin or mucosa.

Such systems often cannot be adequately optimized to control onset of delivery (i.e., slow down or retard) and / or maintain delivery for an extended duration of delivery without compromising other design and performance factors and considerations.

Accordingly, manufacturing a transdermal system using processing solvents and effectively deliver such a drug is even more problematic.

A problem associated with the use of such acrylic-based polymers with functional groups is that due to the generally high solubility of the drug, a large amount of drug generally must be incorporated into the composition to saturate it and provide an adequate drug release to the skin of the user.

In use with low molecular weight drugs or controlled substances, the loss of the drug in the manufacturing process again can be a significant problem.

These drug delivery devices generally do not allow a great amount of flexibility in effectively controlling the release rate of a variety of drugs, which in turn also severely limits their therapeutic application, and are expensive or burdensome to manufacture.

Images